Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegintron in HIV Chronic Infection
NCT01935089Phase 2Completed
- Sponsor
- The Wistar Institute
- Start
- Aug 2013
- Primary completion
- Mar 2015
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of peginterferon alfa-2b in human immunodeficiency virus type 1 infection (HIV-1), sponsored by The Wistar Institute. Primary endpoint: Copies of HIV DNA Per CD4+ T Cell at 24 weeks. Started Aug 2013; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01935089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01935089.